Products and Services
-
Aptar Pharma will co-develop and promote i2c Pharmaceutical Services’ Respitab MDI technology, the two companies have announced. The Respitab system involves formulating the drug as a tablet that can be easily dispensed into an MDI… Read more . . .
-
Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec’s mSAS supercritical fluid particle engineering technology. The first… Read more . . .
-
Pulmodyne and Alcove Manufacturing and Distribution have announced a new partnership for manufacturing and distribution of Alcove’s EZ-Spray intranasal mucosal atomization device and said that Pulmodyne is set to begin manufacturing and distributing EZ-Spray devices… Read more . . .
-
BreatheSuite announced that the FDA has cleared the company’s disposable BreatheSuite MDI device, which attaches to the top of a standard metered dose inhaler canister to provide inhaler usage monitoring and feedback to the patient… Read more . . .
-
The Drug Delivery to the Lungs conference organizing committee and the British Thoracic Society have both announced that they will cut ties with inhalation CDMO Vectura following the company’s acquisition by tobacco company Philip Morris… Read more . . .
-
Dutch vaccine developer Intravacc has announced that it will continue to develop its pipeline of intranasal vaccines while adding a contract development and manufacturing business. The company said that it will offer GMP manufacturing for… Read more . . .
-
According to Adherium, the company has received 510(k) clearance from the FDA for its next generation Hailie inhaler sensor. The new version of the Hailie sensor, which is meant to be used with the Symbicort… Read more . . .
-
Nanoform Finland and Herantis Pharma say that they have successfully demonstrated the feasibility of using Nanoform’s nanoparticle technology for a potential intranasal formulation of Herantis’s cerebral dopamine neurotrophic factor (CDNF) for the treatment of Parkinson’s disease,… Read more . . .
-
Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx’s SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19.… Read more . . .
-
Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland